TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot every 3 months could help hearts in rare disease
Disease control OngoingThis study tests a drug called vutrisiran in people with a rare disease that causes abnormal proteins to build up in the heart, leading to heart failure. The goal is to see if the drug can reduce deaths and heart-related hospital visits. About 655 adults took part, receiving eith…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:18 UTC
-
Heart protein disease drug tested for Long-Term safety in 700 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called vutrisiran in people with a heart condition caused by abnormal protein buildup (ATTR amyloidosis with cardiomyopathy). About 700 adults who were already in related studies will continue or switch to vutri…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:12 UTC